Policy changes Backwork has recorded, newest first. The most recent change on record is from October 2, 2026. Changes appear here after Backwork reviews and applies a refresh, so this page can trail the payers’ own sites.
Summary of the payer’s published policy. Not a coverage determination — confirm with the payer before submitting.
82,180 on record
| Recorded | Payer | Policy | Change |
|---|---|---|---|
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Romidepsin [Istodax; Romidepsin (liquid)] | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Valoctocogene Roxaparvovec‐rvox (Roctavian) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Rituximab Products (Rituxan, Rituximab-abbs [Truxima],Rituximab-arrx [Riabni] and Rituximab-pvvr [Ruxience]) (Oncology Indications) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Rituximab Products (Rituxan, Rituximab-abbs [Truxima],Rituximab-arrx [Riabni] and Rituximab-pvvr [Ruxience]) (Non-Oncology Indications) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Rituximab and Hyaluronidase Human Injection (Rituxan Hycela) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Risankizumab-rzaa (Skyrizi) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Rhinoplasty | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Retinal Telescreening for Diabetic Retinopathy | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Retifanlimab-dlwr (Zynyz) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Remestemcel-L-rknd (Ryoncil) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Ravulizumab-cwvz (Ultomiris) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Ranibizumab (Susvimo) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Ranibizumab (Lucentis, Byooviz; Cimerli) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Radiotherapy for Prostate Cancer | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Radiofrequency Tissue Volume Reduction (RFTVR) for the Treatment of Upper Airway Obstruction | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Radioembolization for Primary Tumors and Metastatic Tumors to the Liver | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Tofersen (Qalsody) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Treprostinil injection (Remodulin); Treprostinil | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Sipuleucel-T (Provenge) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Proton Beam Therapy | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Protein Profiling Assays for Breast Cancer Prognosis | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Prostate Specific Antigen (PSA) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Prademagene Zamikeracel (Zevaskyn) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Pozelimab-bbfg (Veopoz) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Positron Emission Tomography (PET) for Cardiac Applications | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Polatuzumab Vedotin-piiq (Polivy) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Plasminogen, human-tvmh (Ryplazim) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Plasma Exchange | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Pivekimab Sunirine-pvzy (Decnupaz) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Photodynamic Therapy (PDT) for the Treatment of Certain Cancers | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Pharmacogenetic Testing for Pain Management | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Pertuzumab, Trastuzumab and Hyaluronidase-zzxf (Phesgo) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Pertuzumab (Perjeta); Pertuzumab-dpzb (Poherdy) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Peripheral Subcutaneous Field Stimulation for the Treatment of Pain | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Percutaneous Sacroplasty | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Percutaneous Arteriovenous Fistula (pAVF) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Treatment for Sexual Dysfunction in Males: Non-Pharmacologic | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Pemetrexed (Alimta; Pemfexy, Pemetrexed, Pemrydi RTU, Axtle) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Pegcetacoplan (Syfovre) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Sodium Thiosulfate (Pedmark) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Pasireotide (Signifor LAR) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Zopapogene Imadenovec-drba (Papzimeos) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Panitumumab (Vectibix) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Palivizumab (Synagis) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Lumasiran (Oxlumo) | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Osteochondral Autografting | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Piezoelectric Sensor Analysis and Oscillating Force Delivered Vertebral Adjustment in the Evaluation and Treatment of the Spinal Column | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Orthopedic Applications of Stem Cell Therapy | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Orthognathic Surgery | Metadata changed |
| Oct 2, 2026 | BlueCross BlueShield of Tennessee | Oral Negative Pressure Therapy Devices for The Treatment of Sleep Apnea | Metadata changed |